Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate.

Author: AltamuraConcetta, BernasconiPia, CarratùMaria Rosaria, ConteDiana, DesaphyJean-François, FarinatoAlessandro, ImbriciPaola, Lo MonacoMauro, MaggiLorenzo, MantegazzaRenato, PasqualiLivia, SicilianoGabriele, SternbergDamien, VialChristophe

Paper Details 
Original Abstract of the Article :
Sodium channel myotonia and paramyotonia congenita are caused by gain-of-function mutations in the skeletal muscle voltage-gated sodium channel hNav1.4. The first-line drug is the sodium channel blocker mexiletine; however, some patients show side effects or limited responses. We previously showed t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.phrs.2019.01.004

データ提供:米国国立医学図書館(NLM)

Navigating the Complexities of Myotonic Sodium Channels

The world of genetics is a labyrinthine maze, and understanding the nuances of genetic disorders is essential for effective treatment. This study delves into the pharmacogenetics of myotonic hNav1.4 sodium channel variants, focusing on mutations near the fast inactivation gate. The researchers investigated the effects of these mutations on the efficacy of sodium channel blockers, aiming to personalize treatment strategies for patients with myotonic disorders.

Unveiling the Impact of Mutations

The study found that mutations near the fast inactivation gate impair the kinetics and voltage dependence of fast inactivation. This can lead to a range of clinical manifestations, including myotonia. The researchers also discovered that some of these mutations reduce the potency of mexiletine, a commonly used sodium channel blocker, highlighting the need for alternative treatment options.

Tailoring Treatment for a Personalized Approach

The study's findings pave the way for a more personalized approach to managing myotonic disorders. By identifying specific mutations and their impact on drug efficacy, clinicians can select the most appropriate treatment strategy for each patient, optimizing therapeutic outcomes and minimizing side effects. This underscores the growing importance of pharmacogenetics in the personalized medicine era.

Dr.Camel's Conclusion

This research highlights the crucial role of pharmacogenetics in understanding and managing myotonic disorders. By deciphering the complex interactions between mutations and drug efficacy, healthcare providers can navigate the labyrinth of personalized medicine, offering patients more effective and targeted treatments.
Date :
  1. Date Completed 2019-09-03
  2. Date Revised 2019-09-03
Further Info :

Pubmed ID

30611854

DOI: Digital Object Identifier

10.1016/j.phrs.2019.01.004

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.